Clinical Trial News and Research

RSS

Damaged heart tissue is significantly reduced with supersaturated oxygen

Results of a clinical trial published today in Circulation: Cardiovascular Interventions demonstrate that an infusion of blood that is "supersaturated" with oxygen (SS02) can reduce the amount of damaged heart muscle immediately following a life-threatening heart attack

16 Sep 2009

Clinical trial data of Lipsovir presented at ICAAC

Medivir presented Lipsovir (ME-609) at a poster session on 14th September at the ongoing ICAAC (Interscience Conference on Antimicrobial Agents and Chemotherapy) meeting.

16 Sep 2009

Urgent vaccine requirements for treating epidemic diseases voiced at ECI 2009

As a result of dominant media coverage of new epidemic threats such as swine influenza, other infection risks receive less public attention than they deserve. "We would like to bring to everybody's attention that the infectious diseases with the most severe consequences continue to be old acquaintances such as tuberculosis, HIV/AIDS, malaria and hepatitis C. About six million people worldwide die of these diseases every year," says Professor Dr. Dr. h. c. Stefan H. E. Kaufmann, Director of the Max Planck Institute for Infection Biology in Berlin, at the 2nd European Congress of Immunology ECI 2009.

16 Sep 2009

Study reveals effectiveness of cognitive testing by telephone in elderly individuals

Cognitive testing by telephone in elderly individuals is generally as effective as in-person testing, according to a new study by Effie M. Mitsis, PhD, Assistant Professor of Psychiatry at Mount Sinai School of Medicine and part of Mount Sinai's Alzheimer's Disease Research Center. The study will appear in the International Journal of Geriatric Psychiatry.

16 Sep 2009

FDA grants orphan drug status to Advanced Life Sciences' Restanza

Advanced Life Sciences Holdings, Inc. (OTC Bulletin Board: ADLS) today announced that the United States Food and Drug Administration (FDA) has granted Orphan Drug Designation to Restanza(TM) (cethromycin), its novel, once daily oral antibiotic, for the prophylactic treatment of plague and tularemia. Both tularemia and plague are classified by the Centers for Disease Control as Category A Bioterrorism Agents, which is the highest priority classification.

16 Sep 2009

WHO says 3b people worldwide could receive H1N1 vaccine

Recent findings that a single dose of an H1N1 (swine) flu vaccine offers protection against the virus and anticipation of vaccination programs starting earlier than predicted will increase the number of people worldwide with access to the vaccine and the likelihood health officials may be able to control the spread of the virus, Bloomberg reports.

16 Sep 2009

New peptide-based cancer vaccine tested in genital cancer patients

Preventive vaccination against infectious diseases has been a major milestone for the health of modern society. The development of therapeutic vaccination against established diseases is much more difficult. For more than 100 years researchers have already tried to develop cancer vaccines and now first promising clinical results raise hopes. A summary of the most attractive new approaches gave Professor Carmen Scheibenbogen, Institut für Medizinische Immunologie, Charité-Universitätsmedizin, at a press conference in Berlin.

16 Sep 2009

FDA approves BioVex' design of a Phase III clinical trial to evaluate OncoVEX

BioVex Inc, a biotechnology company developing clinical stage treatments for cancer and the prevention of infectious disease, announced today that the U.S. Food and Drug Administration (FDA) has approved the design of a single, pivotal, Phase III clinical trial evaluating its lead product, OncoVEX (GM-CSF), for the first-line treatment of patients with squamous cell cancer of the head and neck.

15 Sep 2009

BCLI collaborates with HBI to complete pre-clinical safety experiments

BrainStorm Cell Therapeutics Inc., a leading developer of adult stem cell technologies and therapeutics, announced today that it has entered into a strategic agreement with Harlan Biotech Israel Ltd (HBI), a leading Good Laboratory Practice contractor, in order to complete pre-clinical safety experiments for the company’s innovative therapy for ALS (Amyotrophic Lateral Sclerosis, also known as Lou Gehrig’s disease).

15 Sep 2009

Alvine Pharmaceuticals raises funds for Phase 2a clinical trial of its lead compound ALV003

Alvine Pharmaceuticals, Inc., a privately held biopharmaceutical company focused on developing and commercializing therapeutics for autoimmune/gastrointestinal diseases, today announced the closing of a $21.5 million extension of its Series A financing.

15 Sep 2009

Hyperion enrolls first patient in HPN-100 investigational compound clinical trial

Hyperion Therapeutics today announced that the first patient has been enrolled in a clinical trial of investigational compound HPN-100 (glycerol phenylbutyrate) in children ages 6-17 with urea cycle disorders (UCD). The study will evaluate the safety, tolerability, and ammonia control of glycerol phenylbutyrate compared to BUPHENYL® (sodium phenylbutyrate).

15 Sep 2009

Palatin Technologies to announce clinical trial results of PL-3994

Palatin Technologies, Inc. (NYSE Amex: PTN) announced that a poster on clinical trial results with PL-3994, its product for heart failure, will be presented today at the 13th Annual Scientific Meeting of the Heart Failure Society of America in Boston.

15 Sep 2009

Implantable defibrillator therapy not beneficial for women with heart failure

Implantable cardioverter-defibrillators do not appear to be associated with a reduced risk of death in women with advanced heart failure, according to a meta-analysis of previously published research in the September 14 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.

15 Sep 2009

Lexicon initiates Phase 2 clinical trial of LX4211 in patients with type 2 diabetes mellitus

Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering breakthrough treatments for human disease, obtained favorable results from recently completed Phase 1 studies of LX4211 and announced today that it has initiated a Phase 2 clinical trial of the drug candidate in patients with type 2 diabetes mellitus.

15 Sep 2009

IMPROVE HF clinical trial results presented at annual HFSA meeting

Twenty-four month findings from IMPROVE HF, (The Registry to Improve the Use of Evidence-Based Heart Failure Therapies in the Outpatient Setting), funded by Medtronic, Inc., demonstrated that clinics using the process improvement program increased adherence to evidence-based, guideline-recommended care by 82 and 62 percent, respectively, for cardiac resynchronization therapy (CRT) and implantable cardioverter-defibrillator (ICD) use, and 80 percent for aldosterone antagonist use, all relative to baseline results.

15 Sep 2009

OptiVol for accurate prediction of heart failure

Fluid monitoring with OptiVol® Fluid Status Monitoring is a more accurate predictor of worsening heart failure compared to daily weight monitoring in heart failure patients with implantable devices, according to results released today from the FAST (Fluid Accumulation Status Trial) clinical trial.

15 Sep 2009

Clinical trial data of Genous Bio-engineered R stent to be presented

Data from multiple clinical trials of the world's first pro-healing stent, OrbusNeich's Genous Bio-engineered R stent, and preclinical data from Combo Bio-engineered Sirolimus Eluting Stent will be presented next week at the Transcatheter Cardiovascular Therapeutics symposium, TCT 2009, in San Francisco.

15 Sep 2009

Targeted Molecular Diagnostics to offer digital pathology services in Beijing

Targeted Molecular Diagnostics (TMD), a Quintiles Central Laboratory, announced today the availability of digital pathology services in Beijing, China. The services add to Quintiles offerings used in the development of therapies to treat the world’s most pressing health issues, including cancer.

15 Sep 2009

NSF International certification for COLD-FX(R)

Afexa Life Sciences Inc. ("Afexa") (TSX:FXA) today announced that COLD-FX(R) has received the highest sports certification in North America from the leading product safety and banned substances testing body for elite athletes.

15 Sep 2009

Triamcinolone may be a treatment option for some patients with retinal vein occlusion

Injecting the eye with the corticosteroid triamcinolone appears effective in improving the vision of some patients with retinal vein occlusion, an important cause of vision loss that results from blockages in the blood vessels in the retina, according to two reports in the September issue of Archives of Ophthalmology, one of the JAMA/Archives journals.

15 Sep 2009